[Interferon and chronic myeloid leukemia].
Steegmann
J L
JL
Servicio de Hematología, Hospital de la Princesa, Madrid.
Pérez Sánchez
M
M
Fernández-Rañada
J M
JM
D000917:Antibody Formation; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001752:Blast Crisis / Q000628:therapy; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D016044:Fusion Proteins, bcr-abl / Q000096:biosynthesis / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007370:Interferon Type I / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D007370:Interferon Type I; D011994:Recombinant Proteins; D016044:Fusion Proteins, bcr-abl
Interferón y leucemia mieloide crónica.